Chikungunya virus (CHIKV) is a mosquito-borne medically important pathogen that affected millions of people around the world. CHIKV infection causes high fever, intense joint pain and often leads to chronic virus-induced arthritis, to which there are no specific treatments or...
Chikungunya virus (CHIKV) is a mosquito-borne medically important pathogen that affected millions of people around the world. CHIKV infection causes high fever, intense joint pain and often leads to chronic virus-induced arthritis, to which there are no specific treatments or cures. We witness recurring epidemics in the world, and with changing climates, it is spreading to wider and wider all the time. It is a debilitating disease and there is a clear necessity to develop antiviral compounds capable of eliminating persisting virus. CHIKV is an alphavirus from Togaviridae family with single-stranded positive-sense RNA genome, which replication is carried out by a complex of four viral non-structural (ns) proteins, initially produced in a form of ns-polyprotein precursor and released by proteolytic processing. Because multifunctional nsP2 plays a central role in a replication cycle of CHIKV by exhibiting various enzymatic activities and counteracting cellular defence mechanisms, it represents the most attractive target for drug design and screening. Therefore the first aim of this project was to apply structural biology approaches to elucidate spatial organization of nsP2 domains. The second aim of the project was to explore the druggability of nsP2 domains by screening recombinant proteins against libraries of chemical fragments and characterizing binding of small molecules using sensitive biophysical techniques and crystallographic analysis.
In Work Package 1 significant efforts were invested into solving numerous problems with protein production and purification for CHIKV proteins. This included creation and implementation of new approaches for enhancing protein solubility by promoting correct folding, identifying mutants and fusion constructs that would result in sufficient amounts of monodisperse proteins needed for crystallization trials. In addition, another set of vectors for co-expression of bacterial chaperones and folding modulators (disulphide isomerases, peptidyl-prolyl isomerases etc) was created and employed throughout the project. The total number of expression constructs for different CHIKV proteins created and tested in this project exceeds 400 and such systematic screening approach allowed us to identify the best expression constructs, the best expression conditions and the best purification schemes for CHIKV proteins which is an absolute necessity for any further studies aiming screening and validation of virus inhibitors. During this project almost 130 96-well crystallization trays using different purified alphavirus proteins were set up and analysed, which constitutes a significant effort in understanding what approaches might be working when CHIKV proteins are concerned. It was found particularly promising to employ fusion partner driven crystallization, which in combination with surface entropy reduction and buffer conditions optimisation by TSA appears to be first choice strategy for difficult targets: to address this, corresponding set of vectors facilitating production of protein of interest fused to crystallization helpers such as MBP, GFP, Trx, Sumo or T4 lysozyme has been created. The obtained deliverables include: purified nsP2 and its domains Pro and N174, several structures of CHIKV Pro alone and as part of fusion construct as well as novel structure of N-terminal domain of nsP2.
Work Package 2 was focused of expression and purification of large polyproteins, which benefited from using codon-optimised genes, introducing different mutations to prevent proteolytic processing and prevent aggregation. In parallel individual CHIKV proteins nsP1 and nsP3 were expressed and purified. Attempts to generate complexes of nsP2 protease and N174 domains with nsP1 and nsP3 were performed using mixed purified components and analytical size exclusion chromatography. Purified nsP1, nsP3 and fusion of nsP1 with N174 or Pro with nsP3 were submitted to crystallization trials and SAXS analysis. The obtained deliverables include: purified polyproteins CHIKV P12, P123, purified proteins nsP1, nsP1-N174, nsP3 and Pro-334 and their SAXS analysis. Importantly, thanks to the development of cryo-EM technique the obtained protein preparations of P12 and P123 can now be analysed using in-house cryo-EM microscope commissioned in April 2018.
In Work Package 3 after optimization of conditions thermal shift assay was performed using CHIKV Pro and in-house library of fragments encompassing 960 chemical compounds. This led to identification of several molecules that act at increasing protein stability, suggesting their binding to the target protein, and large number of compounds potentially destabilising protease domain, possibly binding at the interface between two subdomains of CHIKV Pro and promoting protein unfolding therein. These compounds will be used in the future rounds of validation by complimentary biophysical techniques such as ligand-based NMR.
Finally, Work package 4 dealt with the assay development, whereas protease activity assay based on measurements of changes in fluorescence polarization upon substrate cleavage was created.
The obtained preliminary results have already been used to apply for additional round of funding and it is also expected that novel structural information for N174 domain of CHIKV nsP2 will provide with new ideas regarding its possible role in of CHIKV replication, possibilities for its inhibition and will constitute the basis f
This project resulted in determination of high resolution structures of two domains of Chikungunya virus nsP2: protease domain (Pro), which is considered one the most promising targets for inhibitors of viral enzymatic machinery, and unique N-terminal domain (NTD) of nsP2, which has no homologues outside the Alphavirus genus and therefore offers exceptional opportunity to develop highly specific inhibitors of alphaviral replication. Additionally, newly developed protease activity assay based on measurements of changes in fluorescence polarization upon substrate cleavage is an economically attractive method for profiling of protease enzymatic properties and identification of the inhibitors affecting proteolytic activity. All these deliverables pave the way to screening and development of chemical compounds potentially affecting replication of Chikungunya virus, and possibly other alphaviruses such as Mayaro virus and O’nyong nyong virus, which are the emerging causative agents behind the mosquito-borne diseases that are leading to increasing amount of suffering, in particular in Asia and in South and Central America.